Author  
Place of duty  
Title   Áö¼Ó¼º ¹× Àç¹ß¼º ºÎÀÎ¾Ï Á¦¾î¿¡ ´ëÇÑ Ifosfamide Based Refimens ÀÇ ÀÓ»ó È¿°ú ( Clinical Effect of Ifosfamide Based Refimens for the Management of Recurrent or Persistent Gynecologic Malignancy )
Publicationinfo   1993 Jan; 025(05): 687-696.
Key_word   Ifosfamide, Secand-line of regimen, Persistent and recurrent gynecologic malignancy
Full-Text  
Abstract   alkylating agent ifosfamide, an analog of cyclophosphamide, has demonstrated significant antineoplastic effect is induced by hydroxylation of the 4-carbon in oxazaphosphorine ring and suppression of cellular DNA replication. The combined regimens with ifosfamide have been studied for the management of patients with recurrent or persistent gynecologic malignacies from May l991 through March 1993 at the Department of Obstetrics and Gynecolo- gy, Hanyang University Hospital and the following results were obtained. 1) The clinical responses, 1 complete, and 8 partial responses have been obtained in 9 patients (60%) among 15 patients with persistent or recurrent cervical cancer. The overall median sur- vival was 5+months(range, 2~22+months) and 6 patients are still alive. 2) The clinical responses in the group of ovarian cancer revealed partial responses in 7 pa- tients(70%) among 10 patients, The overall median survival was 16+months(range, 4~23+ months) and 5 patients are still alive. 3) The various toxicities have been noticed in all patient including grade 1~3 gastrointesti- nal toxicity, and bone marrow depression. Furthermore, severe hemorrhagic cystitis was developed in one patient and severe CNS toxicity in four patients. The results showed that the ifosfamide cambination chemotherapy may be an effective second-line regimen in recurrent or persistent gynecologic malignancies. However, the duration of survival has been very short with these schedules and dosages, and the real benefit of combination chemotherapy with the base of ifosfamide should be held until prolangation of survaval is proven objectively following the trials including dose escalation or various biochemical modulation.
Àú ÀÚ   ±è±â¼º(Kee Sung Kim),±è°æÅÂ(Kyung Tai Kim),Á¶»ïÇö(Sam Hyun Cho),À¯Áß¹è(Jung Bae Yoo),ȲÀ±¿µ(Youn Yeung Hwang),¹®Çü(Myung Moon),ÀÌÀç¾ï(Jai Auk Lee)